This installment of our quarterly Trials Update captures the latest developments in Alzheimer’s and other dementia clinical trials, from January 2025 to present. We’ve…
After months of delays, Alzheon gears up to present data from their pivotal Phase 3 drug trial, while Athira Pharma pays out a settlement…
This past three months in the Alzheimer’s drug development space have seen a new FDA approval for a symptomatic treatment, a couple failed phase…
In a recent survey, Being Patient put a question to readers: “What is the biggest barrier preventing you from seeking a trial?” The most…
The monoclonal antibody drugs targeting the brain’s amyloid plaques dominated the news cycle in 2023. Eisai and Biogen’s Leqembi was approved by the FDA…